Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $55.06

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given an average rating of “Moderate Buy” by the seventeen brokerages that are currently covering the stock, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $55.06.

KYMR has been the topic of a number of research analyst reports. Stephens reiterated an “overweight” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Tuesday, January 21st. Truist Financial reiterated a “buy” rating and issued a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a research report on Friday, November 1st. Morgan Stanley raised their target price on shares of Kymera Therapeutics from $45.00 to $49.00 and gave the company an “equal weight” rating in a report on Wednesday, November 6th. Leerink Partners restated an “outperform” rating and set a $60.00 target price on shares of Kymera Therapeutics in a research report on Friday, December 27th. Finally, Guggenheim increased their price target on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research report on Friday, November 1st.

Kymera Therapeutics Price Performance

KYMR opened at $36.81 on Monday. Kymera Therapeutics has a 1-year low of $29.24 and a 1-year high of $53.27. The stock has a market cap of $2.38 billion, a P/E ratio of -15.73 and a beta of 2.18. The stock’s 50 day simple moving average is $39.77 and its 200 day simple moving average is $44.02.

Insider Buying and Selling at Kymera Therapeutics

In other Kymera Therapeutics news, insider Ellen Chiniara sold 3,129 shares of the firm’s stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $41.75, for a total value of $130,635.75. Following the sale, the insider now directly owns 54,826 shares of the company’s stock, valued at approximately $2,288,985.50. This trade represents a 5.40 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.82% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of KYMR. Blue Trust Inc. boosted its holdings in shares of Kymera Therapeutics by 74.8% in the 4th quarter. Blue Trust Inc. now owns 631 shares of the company’s stock valued at $25,000 after purchasing an additional 270 shares during the last quarter. Summit Investment Advisors Inc. boosted its holdings in Kymera Therapeutics by 9.0% in the fourth quarter. Summit Investment Advisors Inc. now owns 4,912 shares of the company’s stock valued at $198,000 after acquiring an additional 406 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in Kymera Therapeutics by 27.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,336 shares of the company’s stock valued at $114,000 after acquiring an additional 504 shares during the period. Harbor Capital Advisors Inc. increased its stake in Kymera Therapeutics by 1.7% during the fourth quarter. Harbor Capital Advisors Inc. now owns 40,987 shares of the company’s stock worth $1,649,000 after acquiring an additional 684 shares during the last quarter. Finally, KBC Group NV raised its holdings in shares of Kymera Therapeutics by 53.8% in the 4th quarter. KBC Group NV now owns 2,151 shares of the company’s stock worth $87,000 after purchasing an additional 752 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.